BUZZ-Lipella jumps after inflammatory disease drug found safe in study

Shares of Pittsburgh-based drug developer Lipella Pharmaceuticals LIPO.O rise 68.20% to $5.14 premarket

LIPO says its experimental drug, LP-310, showed a strong safety profile in a small study of 24 patients with oral lichen planus (OLP), a chronic inflammatory disease that affects mucous membranes inside the mouth

Co says no drug-related serious adverse events were found in study, and no patients dropped out

LIPO says LP-310, an oral rinse topical treatment, helped meaningfully reduce pain, ulceration, and inflammation for patients in the study

Co plans to submit marketing application for LP-310 to the FDA in H2 2025

In the last 12 months, the stock has fallen 63.34%